Valuation check: RAIN's debt-to-equity ratio is -0.0, below the Healthcare sector average of 0.34.
Get informed when a big investor buys or sells
+ Follow0.00
Debt-to-Equity ratio measures a company's financial leverage by comparing its total debt to shareholder equity. A lower D/E ratio generally indicates a more financially stable company with less risk.
As of the most recent data, RAIN shows a debt-to-equity ratio of -0.0. That is below the Healthcare sector average of 0.34. Scroll down for historical charts and peer comparison views.
The Healthcare sector average debt-to-equity ratio is about 0.34. Rain Oncology is at -0.0, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how RAIN stacks up against individual peers as well.
Investors watch RAIN's debt-to-equity ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Rain Oncology's latest reading is -0.0. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this debt-to-equity ratio page, Stockcircle has Rain Oncology's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect debt-to-equity ratio (currently -0.0) with ownership activity and broader fundamentals.
The Healthcare average debt-to-equity ratio is about 0.34, while RAIN is at -0.0. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.